ImmunoGen AI
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $65M
Overview
Using AI/ML to discover and design novel antibody therapeutics for oncology.
Oncology
Technology Platform
AI/ML platform for the in silico design, optimization, and discovery of therapeutic antibodies against cancer targets.
Funding History
1Total raised:$65M
IPO$65M
Opportunities
Potential to rapidly generate high-quality antibody candidates against difficult targets and partner with larger pharma companies.
Risk Factors
Risk that AI-designed antibodies may not translate to expected efficacy or safety in biological systems and clinical trials.
Competitive Landscape
Part of a growing field of AI-driven drug discovery companies, competing on the accuracy and throughput of its predictive models.